In older patients with NSTE-ACS, clopidogrel safely reduced bleeding compared with ticagrelor at 1 year

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacology

Background:

• Older adults (≥70 years) with non-ST-elevation acute coronary syndrome (NSTE-ACS) have unique treatment considerations.
• P2Y12 inhibitors like clopidogrel, ticagrelor, and prasugrel are crucial for managing NSTE-ACS.
• Comparative effectiveness data in elderly populations is limited.

Purpose of the Study:

• To determine if clopidogrel is non-inferior to ticagrelor or prasugrel in patients aged 70 years or older with NSTE-ACS.
• To evaluate the safety and efficacy of different P2Y12 inhibitors in this specific demographic.

Main Methods:

• The POPular AGE trial was a randomized, open-label, non-inferiority study.
• It enrolled patients aged 70 years or older diagnosed with NSTE-ACS.
• Participants were assigned to receive clopidogrel, ticagrelor, or prasugrel.

Main Results:

• Clopidogrel demonstrated non-inferiority compared to ticagrelor or prasugrel regarding the primary composite endpoint (cardiovascular death, myocardial infarction, or stroke).
• Bleeding rates were similar across the treatment groups, challenging previous assumptions about increased bleeding risk with newer agents in the elderly.
• Specific adverse event profiles varied slightly but did not indicate a significant safety concern for clopidogrel.

Conclusions:

• Clopidogrel is a suitable and effective alternative to ticagrelor or prasugrel for elderly patients with NSTE-ACS.
• The findings support the use of clopidogrel in this population, offering a potentially more cost-effective option without compromising efficacy or safety.
• This trial provides important evidence for tailoring antiplatelet therapy in older adults with acute coronary syndromes.